Securities Fraud Class Action filed against Sarepta Therapeutics, Inc.

A securities fraud class action lawsuit has been filed against Sarepta Therapeutics, Inc. (SRPT), prompting Levi & Korsinsky to remind investors of the August 25, 2025 deadline for filing claims. The lawsuit alleges that the company made false and misleading statements regarding the efficacy and prospects of its gene therapy for Duchenne muscular dystrophy.

Investors who purchased Sarepta stock between May 20, 2020, and August 6, 2025, are encouraged to participate in the class action suit. The complaint specifically points to Sarepta’s failure to disclose crucial information about the gene therapy’s performance in clinical trials, leading to artificially inflated stock prices.

The lawsuit claims that Sarepta engaged in misleading marketing tactics to create a positive outlook for the gene therapy, despite knowing about its shortcomings. The company’s failure to disclose this information resulted in financial harm to investors who relied on inaccurate statements to make investment decisions.

Sarepta’s stock prices plummeted after the truth about the gene therapy’s performance became public knowledge. Investors who suffered financial losses as a result of these misleading statements are eligible to join the class action lawsuit. By participating in the legal action, investors can seek compensation for their losses caused by Sarepta’s alleged securities fraud.

Levi & Korsinsky are urging investors to act before the August 25, 2025, deadline to ensure they are included in the class action suit. The law firm specializes in representing shareholders who have been victims of securities fraud and is dedicated to holding companies accountable for their deceptive practices.

Investors who believe they have been harmed by Sarepta’s misleading statements are encouraged to contact Levi & Korsinsky to discuss their legal options. By joining the class action lawsuit, investors can pursue justice and potentially recover financial losses incurred as a result of Sarepta’s alleged securities fraud.

The securities fraud class action lawsuit against Sarepta Therapeutics, Inc. serves as a reminder of the importance of transparency and honesty in the financial markets. Investors rely on accurate information to make informed decisions, and companies have a responsibility to disclose material facts that could impact stock prices.

Levi & Korsinsky’s efforts to hold Sarepta accountable for its alleged securities fraud demonstrate their commitment to protecting investors’ rights and seeking justice for those who have suffered financial harm. By taking legal action against companies that engage in deceptive practices, investors can help prevent future instances of securities fraud and promote greater accountability in the financial industry.